Metformin use improves survival of diabetic liver cancer patients: Systematic review and meta-analysis

Oncotarget

Volumn 7, Issue 40, 2016, Pages 66202-66211

  Ma, Shu Juan ^a   Zheng, Yi Xiang ^b   Zhou, Peng Cheng ^b   Xiao, Yan Ni ^a   Tan, Hong Zhuan ^a  

^a CENTRAL SOUTH UNIVERSITY   (China)

^b CENTRAL SOUTH UNIVERSITY   (China)

Author keywords

Diabetes mellitus; Liver cancer; Meta analysis; Metformin; Survival

Indexed keywords

METFORMIN; ANTIDIABETIC AGENT;

ARTICLE; CANCER MORTALITY; CANCER PATIENT; DIABETES MELLITUS; DRUG USE; HUMAN; LIVER CANCER; META ANALYSIS; OBSERVATIONAL STUDY; SURVIVAL; SYSTEMATIC REVIEW; COMPLICATION; LIVER TUMOR; NON INSULIN DEPENDENT DIABETES MELLITUS; PROGNOSIS;

DIABETES MELLITUS, TYPE 2; HUMANS; HYPOGLYCEMIC AGENTS; LIVER NEOPLASMS; METFORMIN; PROGNOSIS;

EID: 84994168630     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.11033     Document Type: Article

References (53)

1. El-Serag HB, Mason AC and Key C. Trends in survival of patients with hepatocellular carcinoma between 1977 and 1996 in the United States. Hepatology (Baltimore, Md). 2001; 33:62-65.
2. Richardson LC and Pollack LA. Therapy insight: Influence of type 2 diabetes on the development, treatment and outcomes of cancer. Nature clinical practice Oncology. 2005; 2:48-53.
3. Barone BB, Yeh HC, Snyder CF, Peairs KS, Stein KB, Derr RL, WolffAC and Brancati FL. Long-term all-cause mortality in cancer patients with preexisting diabetes mellitus: a systematic review and meta-analysis. Jama. 2008; 300:2754-2764.
4. Siegel RL, Miller KD and Jemal A. Cancer statistics, 2015. CA Cancer J Clin. 2015; 65:5-29.
5. Giovannucci E, Harlan DM, Archer MC, Bergenstal RM, Gapstur SM, Habel LA, Pollak M, Regensteiner JG and Yee D. Diabetes and cancer: a consensus report. Diabetes care. 2010; 33:1674-1685.
6. Tseng CH. Metformin may reduce oral cancer risk in patients with type 2 diabetes. Oncotarget. 2016; 7:2000-2008 doi: 10.18632/oncotarget.6626.
7. Singh S, Singh PP, Singh AG, Murad MH and Sanchez W. Anti-diabetic medications and the risk of hepatocellular cancer: a systematic review and meta-analysis. The American journal of gastroenterology. 2013; 108:881-891.
8. Yin M, Zhou J, Gorak EJ and Quddus F. Metformin is associated with survival benefit in cancer patients with concurrent type 2 diabetes: a systematic review and metaanalysis. The oncologist. 2013; 18:1248-1255.
9. He XK, Su TT, Si JM and Sun LM. Metformin Is Associated With Slightly Reduced Risk of Colorectal Cancer and Moderate Survival Benefits in Diabetes Mellitus: A Meta-Analysis. Medicine. 2016; 95:e2749.
10. Stopsack KH, Ziehr DR, Rider JR and Giovannucci EL. Metformin and prostate cancer mortality: a meta-analysis. Cancer causes & control. 2016; 27:105-113.
11. Xu H, Chen K, Jia X, Tian Y, Dai Y, Li D, Xie J, Tao M and Mao Y. Metformin Use Is Associated With Better Survival of Breast Cancer Patients With Diabetes: A Meta-Analysis. The oncologist. 2015; 20:1236-1244.
12. Wan G, Yu X, Chen P, Wang X, Pan D, Wang X, Li L, Cai X and Cao F. Metformin therapy associated with survival benefit in lung cancer patients with diabetes. 2016; doi: 10.18632/oncotarget.8881.
13. Zhang P, Li H, Tan X, Chen L and Wang S. Association of metformin use with cancer incidence and mortality: a metaanalysis. Cancer epidemiology. 2013; 37:207-218.
14. Zheng L, Yang W, Wu F, Wang C, Yu L, Tang L, Qiu B, Li Y, Guo L, Wu M, Feng G, Zou D and Wang H. Prognostic significance of AMPK activation and therapeutic effects of metformin in hepatocellular carcinoma. Clinical cancer research. 2013; 19:5372-5380.
15. Nerstedt A, Cansby E, Amrutkar M, Smith U and Mahlapuu M. Pharmacological activation of AMPK suppresses inflammatory response evoked by IL-6 signalling in mouse liver and in human hepatocytes. Molecular and cellular endocrinology. 2013; 375:68-78.
16. Sui X, Xu Y, Wang X, Han W, Pan H and Xiao M. Metformin: A Novel but Controversial Drug in Cancer Prevention and Treatment. Molecular Pharmaceutics. 2015; 12:3783-3791.
17. Qu Z, Zhang Y, Liao M, Chen Y, Zhao J and Pan Y. In vitro and in vivo antitumoral action of metformin on hepatocellular carcinoma. Hepatology research. 2012; 42:922-933.
18. Chen TM, Lin CC, Huang PT and Wen CF. Metformin associated with lower mortality in diabetic patients with early stage hepatocellular carcinoma after radiofrequency ablation. Journal of gastroenterology and hepatology. 2011; 26:858-865.
19. Bhat M, Chaiteerakij R, Harmsen WS, Schleck CD, Yang JD, Giama NH, Therneau TM, Gores GJ and Roberts LR. Metformin does not improve survival in patients with hepatocellular carcinoma. World journal of gastroenterology. 2014; 20:15750-15755.
20. Casadei Gardini A, Marisi G, Scarpi E, Scartozzi M, Faloppi L, Silvestris N, Masi G, Vivaldi C, Brunetti O, Tamberi S, Foschi FG, Tamburini E, Tenti E, et al. Effects of metformin on clinical outcome in diabetic patients with advanced HCC receiving sorafenib. Expert opinion on pharmacotherapy. 2015; 16:2719-2725.
21. Yang Z, Zhang X, Roberts LR and Chaiteerakij R. Metformin Use Reduces Intrahepatic Cholangiocarcinoma Risk in Patients With Diabetes but Does Not Improve Survival of Cholangiocarcinoma. Gastroenterology. 2015; 148:1029-1030.
22. Chaiteerakij R, Baichoo E and Roberts LR. Metformin use improves survival of cholangiocarcinoma (CC) patients with type II diabetes (DM). Hepatology (Baltimore, Md). 2013; 58:331-332.
23. Akmal K, Hassabo H, Botrus G, Shah N, Soliman K, Khalaf R, Li D, Kaseb A and Hassan M. Impact of metformin on HCC prognosis. American Association for Cancer Research. 2012; 72.
24. Currie CJ, Poole CD, Jenkins-Jones S, Gale EA, Johnson JA and Morgan CL. Mortality after incident cancer in people with and without type 2 diabetes: impact of metformin on survival. Diabetes care. 2012; 35:299-304.
25. Hassabo HM, Iwasaki M, Soliman K, Abaza Y, Kaseb AO, Torres HA, Li D, Xiao L, Morris JS and Hassan M. Impact of metformin on HCC prognosis in presence and absence of HCV infection. Hepatology (Baltimore, Md). 2012; 56:457-458.
26. Graef S, Berhane S, Joey Teng M, Skowronska A and Johnson PJ. The impact of diabetes on HCC. American Society of Clinical Oncology. 2013; 31.
27. Ampuero J, Calle R, Figueruela B, Ferrero P, Suarez E and Romero-Gomez M. Statins and metformin use improve prognosis after diagnosis of hepatocelullar carcinoma. Hepatology (Baltimore, Md). 2014; 60:877-877.
28. Jang WI, Kim M-S, Lim JS, Yoo HJ, Seo YS, Han CJ, Park SC, Kay CS, Kim M, Jang HS, Lee DS, Chang AR and Park HJ. Survival Advantage Associated with Metformin Usage in Hepatocellular Carcinoma Patients Receiving Radiotherapy: A Propensity Score Matching Analysis. 2015; 35:5047-5054.
29. Yang Z, Zhang X, Roberts RO, Roberts LR and Chaiteerakij R. Metformin does not improve survival of cholangiocarcinoma in persons with diabetes. Hepatology (Baltimore, Md). 2015; 63:667-668.
30. Seo YS, Kim YJ, Kim MS, Suh KS, Kim SB, Han CJ, Kim YJ, Jang WI, Kang SH, Tchoe HJ, Park CM, Jo AJ, Kim HJ, et al. Association of Metformin Use With Cancer-Specific Mortality in Hepatocellular Carcinoma After Curative Resection: A Nationwide Population-Based Study. Medicine. 2016; 95:e3527.
31. Sadeghi N, Abbruzzese JL, Yeung SC, Hassan M and Li D. Metformin use is associated with better survival of diabetic patients with pancreatic cancer. Clinical cancer research. 2012; 18:2905-2912.
32. Spillane S, Bennett K, Sharp L and Barron TI. A cohort study of metformin exposure and survival in patients with stage I-III colorectal cancer. Cancer epidemiology, biomarkers & prevention. 2013; 22:1364-1373.
33. Margel D, Urbach DR, Lipscombe LL, Bell CM, Kulkarni G, Austin PC and Fleshner N. Metformin use and all-cause and prostate cancer-specific mortality among men with diabetes. Journal of clinical oncology. 2013; 31:3069-3075.
34. Kumar S, Meuter A, Thapa P, Langstraat C, Giri S, Chien J, Rattan R, Cliby W and Shridhar V. Metformin intake is associated with better survival in ovarian cancer: a casecontrol study. Cancer. 2013; 119:555-562.
35. Skinner HD, Crane CH, Garrett CR, Eng C, Chang GJ, Skibber JM, Rodriguez-Bigas MA, Kelly P, Sandulache VC, Delclos ME, Krishnan S and Das P. Metformin use and improved response to therapy in rectal cancer. Cancer medicine. 2013; 2:99-107.
36. Pawlyk AC, Giacomini KM, McKeon C, Shuldiner AR and Florez JC. Metformin pharmacogenomics: current status and future directions. Diabetes. 2014; 63:2590-2599.
37. Pollak M. The insulin and insulin-like growth factor receptor family in neoplasia: an update. Nature reviews Cancer. 2012; 12:159-169.
38. Martin-Castillo B, Vazquez-Martin A, Oliveras-Ferraros C and Menendez JA. Metformin and cancer: doses, mechanisms and the dandelion and hormetic phenomena. Cell cycle (Georgetown, Tex). 2010; 9:1057-1064.
39. Groenendijk FH, Mellema WW, van der Burg E, Schut E, Hauptmann M, Horlings HM, Willems SM, van den Heuvel MM, Jonkers J, Smit EF and Bernards R. Sorafenib synergizes with metformin in NSCLC through AMPK pathway activation. International journal of cancer. 2015; 136:1434-1444.
40. Baffy G, Brunt EM and Caldwell SH. Hepatocellular carcinoma in non-alcoholic fatty liver disease: an emerging menace. Journal of hepatology. 2012; 56:1384-1391.
41. Wang YG, Wang P, Wang B, Fu ZJ, Zhao WJ and Yan SL. Diabetes mellitus and poorer prognosis in hepatocellular carcinoma: a systematic review and meta-analysis. PloS one. 2014; 9:e95485.
42. Ng KK, Poon RT, Lo CM, Yuen J, Tso WK and Fan ST. Analysis of recurrence pattern and its influence on survival outcome after radiofrequency ablation of hepatocellular carcinoma. Journal of gastrointestinal surgery. 2008; 12:183-191.
43. Lencioni R, Cioni D, Crocetti L, Franchini C, Pina CD, Lera J and Bartolozzi C. Early-stage hepatocellular carcinoma in patients with cirrhosis: long-term results of percutaneous image-guided radiofrequency ablation. Radiology. 2005; 234:961-967.
44. Takahashi S, Kudo M, Chung H, Inoue T, Ishikawa E, Kitai S, Tatsumi C, Ueda T, Minami Y, Ueshima K and Haji S. Initial treatment response is essential to improve survival in patients with hepatocellular carcinoma who underwent curative radiofrequency ablation therapy. Oncology. 2007; 72:98-103.
45. Chen TM, Chang TM, Huang PT, Tsai MH, Lin LF, Liu CC, Ho KS, Siauw CP, Chao PL and Tung JN. Management and patient survival in hepatocellular carcinoma: does the physician's level of experience matter? Journal of gastroenterology and hepatology. 2008; 23:e179-188.
46. Johnson JA and Gale EA. Diabetes, insulin use, and cancer risk: are observational studies part of the solution-or part of the problem? Diabetes. 2010; 59:1129-1131.
47. Walker JJ, Johnson JA and Wild SH. Diabetes treatments and cancer risk: the importance of considering aspects of drug exposure. The lancet Diabetes & endocrinology. 2013; 1:132-139.
48. Stang A. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. European journal of epidemiology. 2010; 25:603-605.
49. Guyot P, Ades AE, Ouwens MJ and Welton NJ. Enhanced secondary analysis of survival data: reconstructing the data from published Kaplan-Meier survival curves. BMC medical research methodology. 2012; 12:9.
50. Higgins JP, Thompson SG, Deeks JJ and Altman DG. Measuring inconsistency in meta-analyses. BMJ (Clinical research ed). 2003; 327:557-560.
51. Mantel N and Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. Journal of the National Cancer Institute. 1959; 22:719-748.
52. Egger M, Davey Smith G, Schneider M and Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ (Clinical research ed). 1997; 315:629-634.
53. Begg CB and Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics. 1994; 50:1088-1101.